

## Remedy - Lowered budget assumptions on key projects

Redeye keeps its valuation range and base case unchanged despite a lowered revenue and EBIT expectation in 2023. Since decreased budget assumptions only have an impact on Remedy's short-term revenue, we are still optimistic regarding its more long-term prospects, due to the fact that a lower budget in our view increases the royalty opportunity.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**Remedy - Lowered budget assumptions on key projects**